DexCom, Inc. $DXCM Position Boosted by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 27.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,280 shares of the medical device company’s stock after purchasing an additional 1,370 shares during the period. Cullen Frost Bankers Inc.’s holdings in DexCom were worth $548,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of DXCM. Nuveen LLC bought a new position in shares of DexCom during the first quarter worth about $554,893,000. Jennison Associates LLC raised its holdings in shares of DexCom by 37.7% during the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock worth $718,632,000 after purchasing an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of DexCom by 171.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock worth $218,175,000 after purchasing an additional 2,015,971 shares during the period. Federated Hermes Inc. raised its holdings in shares of DexCom by 2,371.4% during the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock worth $136,220,000 after purchasing an additional 1,914,019 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after purchasing an additional 1,868,241 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock worth $564,733 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Down 1.0%

DXCM stock opened at $70.33 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm’s 50-day simple moving average is $72.37 and its 200 day simple moving average is $77.78. The stock has a market cap of $27.58 billion, a PE ratio of 48.84, a price-to-earnings-growth ratio of 1.49 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter last year, the company earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $106.00 target price on shares of DexCom in a report on Monday, September 29th. Cowen reissued a “buy” rating on shares of DexCom in a report on Friday. Citigroup dropped their target price on shares of DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Morgan Stanley increased their target price on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Finally, Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $97.19.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.